CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company.
CytomX Therapeutics’ latest clinical trial update covers its Phase 1a study of CX-904, a cancer treatment in development. The company notes that the current results show a favorable safety profile and anti-cancer activity.
However, diving into the data better explains why investors aren’t happy. Of the six pancreatic cancer patients able to be evaluated by the cutoff date, only two saw confirmed partial responses. That’s not giving CTMX stockholders hope for positive results from this trial.
Expanding on that, eight patients saw measurable tumor reduction in the cutoff date of the clinical trial. To put that in perspective, the company has enrolled 35 patients in this clinical study.
https://investorplace.com/2024/05/why-is-cytomx-ctmx-stock-down-43-today/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.